8BUKOFZER S, AYRES J, CHAVEZ A, et al. Industry perspective on the medical risk of visible particles in injectable drug products[J]. PDA J Pharm Sci Technol, 2015, 69(1): 123-139.
9STEVEN LYNN. FDA Office of Manufacturing and Product Quality Poster[EB/OL].[2013-03]. http://www.pda.org/docs/default-source/website-document-library/chapters/presentations/new-england/hot-topics-in-visual-inspections.pdf?sfvrsn=4.
10Recalls, Market Withdrawals & Safety Alerts. U.S. Food and Drug Administration[EB/OL].[2015-04-11].http://www.fda.gov/Safety/Recalls/default.htm.
